These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 15190515)

  • 1. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
    Spivak JL
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloproliferative disorders.
    Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
    Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders.
    Kralovics R; Buser AS; Teo SS; Coers J; Tichelli A; van der Maas AP; Skoda RC
    Blood; 2003 Sep; 102(5):1869-71. PubMed ID: 12730106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.
    Kralovics R; Skoda RC
    Blood Rev; 2005 Jan; 19(1):1-13. PubMed ID: 15572213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
    Spivak JL
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):1-5. PubMed ID: 12682874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of clonal development in chronic myeloproliferative disorders.
    Ferraris AM; Mangerini R; Racchi O; Rapezzi D; Rolfo M; Casciaro S; Gaetani GF
    Am J Hematol; 1999 Feb; 60(2):158-60. PubMed ID: 9929111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders.
    Duensing S; Duensing A; Meran JG; Kreft A; Büsche G; Ganser A; Georgii A
    Mol Pathol; 1999 Jun; 52(3):146-50. PubMed ID: 10621836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Mesa RA
    Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
    Moliterno AR; Hankins WD; Spivak JL
    N Engl J Med; 1998 Feb; 338(9):572-80. PubMed ID: 9475764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.
    Goerttler PS; Steimle C; März E; Johansson PL; Andreasson B; Griesshammer M; Gisslinger H; Heimpel H; Pahl HL
    Blood; 2005 Oct; 106(8):2862-4. PubMed ID: 15985544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
    Kaban K; Kantarjian H; Talpaz M; O'Brien S; Cortes J; Giles FJ; Pierce S; Albitar M
    Cancer; 2000 Feb; 88(3):570-6. PubMed ID: 10649249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a molecular understanding of polycythemia rubra vera.
    Pahl HL
    Eur J Biochem; 2000 Jun; 267(12):3395-401. PubMed ID: 10848954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.
    Mitterbauer G; Winkler K; Gisslinger H; Geissler K; Lechner K; Mannhalter C
    Am J Clin Pathol; 1999 Jul; 112(1):93-100. PubMed ID: 10396290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
    Yung Y; Lee E; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.
    Moliterno AR; Williams DM; Rogers O; Spivak JL
    Blood; 2006 Dec; 108(12):3913-5. PubMed ID: 16912229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.
    Liu E; Jelinek J; Pastore YD; Guan Y; Prchal JF; Prchal JT
    Blood; 2003 Apr; 101(8):3294-301. PubMed ID: 12515724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.